Prior research indicates that small-cell lung cancers (SCLCs) exhibit significant sensitivity to Aurora A kinase inhibition, resulting in multiple clinical trials evaluating this treatment in SCLC [126,127,128,129,130,131,132]. The gene discussed is AURKA; the disease is small cell lung carcinoma.